MX2024008450A - Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones - Google Patents

Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones

Info

Publication number
MX2024008450A
MX2024008450A MX2024008450A MX2024008450A MX2024008450A MX 2024008450 A MX2024008450 A MX 2024008450A MX 2024008450 A MX2024008450 A MX 2024008450A MX 2024008450 A MX2024008450 A MX 2024008450A MX 2024008450 A MX2024008450 A MX 2024008450A
Authority
MX
Mexico
Prior art keywords
purine
piperidinyl
methyl
treatment
deuterium
Prior art date
Application number
MX2024008450A
Other languages
English (en)
Spanish (es)
Inventor
Terrence Joseph Connolly
Chad Arthur Lewis
Original Assignee
K36 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K36 Therapeutics Inc filed Critical K36 Therapeutics Inc
Publication of MX2024008450A publication Critical patent/MX2024008450A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024008450A 2022-01-05 2024-07-04 Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones MX2024008450A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263296676P 2022-01-05 2022-01-05
PCT/US2023/010204 WO2023133201A1 (en) 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions

Publications (1)

Publication Number Publication Date
MX2024008450A true MX2024008450A (es) 2024-12-06

Family

ID=87074217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008450A MX2024008450A (es) 2022-01-05 2024-07-04 Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones

Country Status (10)

Country Link
US (2) US12492203B2 (enExample)
EP (1) EP4460502A4 (enExample)
JP (1) JP2025504379A (enExample)
KR (1) KR20240158230A (enExample)
CN (1) CN119032094A (enExample)
AU (1) AU2023205553A1 (enExample)
CA (1) CA3242612A1 (enExample)
IL (1) IL314062A (enExample)
MX (1) MX2024008450A (enExample)
WO (1) WO2023133201A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CN120641105A (zh) * 2022-12-12 2025-09-12 K36治疗股份有限公司 含有哌啶基甲基嘌呤胺的药物组合物及其在治疗疾病和疾患中的用途
AU2024381513A1 (en) * 2023-11-17 2026-06-04 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025259850A1 (en) * 2024-06-12 2025-12-18 K36 Therapeutics, Inc. Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CN114981270B (zh) 2019-09-20 2024-10-18 诺华公司 Mll1抑制剂和抗癌剂
AR122159A1 (es) 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
US20250326752A1 (en) 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
JP2025517349A (ja) 2022-05-18 2025-06-05 ケイ３６・セラピューティクス・インコーポレイテッド ピペリジニル－メチル－プリンアミンｄ－酒石酸塩、結晶形態、ならびに医学的疾患及び状態の治療におけるそれらの使用
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023230038A1 (en) 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
US20250361235A1 (en) 2022-05-23 2025-11-27 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2024055048A1 (en) 2022-09-09 2024-03-14 The Trustees Of Columbia University In The City Of New York Methods of treating neuroendocrine prostate cancer (nepc) by inhibiting nuclear receptor binding set domain protein 2 (nsd2)
CN120641105A (zh) 2022-12-12 2025-09-12 K36治疗股份有限公司 含有哌啶基甲基嘌呤胺的药物组合物及其在治疗疾病和疾患中的用途
AU2024381513A1 (en) 2023-11-17 2026-06-04 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions

Also Published As

Publication number Publication date
CA3242612A1 (en) 2023-07-13
EP4460502A1 (en) 2024-11-13
US20260049083A1 (en) 2026-02-19
CN119032094A (zh) 2024-11-26
US20240352017A1 (en) 2024-10-24
JP2025504379A (ja) 2025-02-12
AU2023205553A1 (en) 2024-07-25
WO2023133201A1 (en) 2023-07-13
US12492203B2 (en) 2025-12-09
KR20240158230A (ko) 2024-11-04
IL314062A (en) 2024-09-01
EP4460502A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ZA202204941B (en) Cd73 inhibitors
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP109934A (es) Compuesto - 946
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CL2004000732A1 (es) Compuestos derivados de oximas sustituidas y sus sales farmaceuticamente aceptables; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los contiene; y uso de los compuestos para el tratamiento del cancer.
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
MX2019013893A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
CR20180493A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
EA201990949A1 (ru) Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине
MX2021005535A (es) Compuestos antibióticos, métodos de fabricacion de los mismos, composiciones farmacéuticas contienendo los mismos y usos de los mismos.
MX386761B (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo.
CO2024009144A2 (es) Inhibidores de cinasa met
CA3242612A1 (en) Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer